| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 29th January 2021 | Anirvan Ghosh | 250,000 | Grant/award etc. | $0.00 | |
| 16th December 2020 | Nathaniel E David | 1,700,000 | Open or private sale | $5.24 | $8,908,000.00 |
| 13th September 2020 | Anirvan Ghosh | 300,000 | Grant/award etc. | $0.00 | |
| 13th September 2020 | Lynne Marie Sullivan | 240,000 | Grant/award etc. | $0.00 | |
| 13th September 2020 | Jamie Dananberg | 240,000 | Grant/award etc. | $0.00 | |
| 13th September 2020 | Alexander Azoy | 135,000 | Grant/award etc. | $0.00 | |
| 9th September 2020 | Ii Robert C. Goeltz | 5,000 | Open or private purchase | $21.57 | $107,848.50 |
| 22nd June 2020 | Ii Robert C. Goeltz | 2,483 | Payment by withholding | $9.67 | $24,010.61 |
| 22nd June 2020 | Jamie Dananberg | 2,483 | Payment by withholding | $9.67 | $24,010.61 |
| 22nd June 2020 | Nathaniel E David | 2,483 | Payment by withholding | $9.67 | $24,010.61 |
Unity Biotechnology
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Unity Biotechnology, Inc. operates as a biotechnology company. The company was founded by Nathaniel David, Jan van Deursen, Judith Campisi and Daohong Zhou in March 2009 and is headquartered in Brisbane, CA.
Ticker: UBX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1463361
Employees: 98
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $40 M (0%)
Marketable Securities, Current: $72 M (-14%)
Assets, Current: $124 M (-4%)
Property, Plant and Equipment, Net: $14 M (-14%)
Other Assets, Noncurrent: $598 Th (-4%)
Assets: $165 M (8%)
Accounts Payable, Current: $4 M (-23%)
Accrued Liabilities, Current: $6 M (25%)
Liabilities, Current: $16 M (-8%)
Liabilities: $52 M (71%)
Common Stock, Value, Issued: $5 Th (0%)
Common Stock, Shares, Issued: $52 M (9%)
Additional Paid in Capital, Common Stock: $405 M (10%)
Retained Earnings (Accumulated Deficit): $292 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $232 Th (157%)
Stockholders' Equity (Parent): $112 M (0%)
Liabilities and Equity: $165 M (8%)
Research and Development: $16 M (-54%)
General and Administrative Expenses: $6 M (-48%)
Operating Income/Loss: $23 M (-53%)
News
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
24th February 2021
Week In Review: Beijing's Jacobio Completes $174 Million Hong Kong IPO
27th December 2020
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
16th December 2020